Dyadic Intl Inc Del Stock Price, News & Analysis

Dyadic International, Inc. (NASDAQ: DYAI) will report its financial results for the first quarter of 2023 on May 10, 2023, at 5:00 p.m. ET. This follows the company's focus on innovative microbial platforms aimed at increasing global protein bioproduction and improving access to biopharmaceutical products for human and animal health. Dyadic utilizes advanced technology based on the fungus Thermothelomyces heterothallica, enhancing the development and manufacturing of biologics. Their lead asset, DYAI-100, is a COVID-19 vaccine candidate, showcasing the company's commitment to addressing unmet clinical needs. A webcast of the conference call will be available post-event for investors and stakeholders.

Dyadic International, Inc. (NASDAQ: DYAI) announced a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled "PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA." This patent is expected to provide protection through 2038 and covers the development and manufacture of seasonal and pandemic influenza vaccines using Dyadic’s C1 protein production platform. The human influenza vaccine market is valued at approximately $8 billion, projected to exceed $12 billion by 2028. CEO Mark Emalfarb highlighted the urgent need for efficient vaccine manufacturing platforms, especially in light of recent health crises. The patent strengthens Dyadic's intellectual property, bolstering its capacity to produce antigens and therapeutic proteins across diverse applications including oncology and diabetes.

Dyadic International (NASDAQ: DYAI) has expanded its licensing agreement with Rubic One Health to enhance the development and distribution of vaccines and biologics for human and animal health in Africa. This agreement builds on a previous collaboration focused on COVID-19 vaccines and now encompasses a wider range of therapeutic proteins beyond COVID-19.

As part of the deal, Dyadic will gain marketing rights and receive milestone and royalty payments from Rubic. The partnership aims to leverage Dyadic’s C1-cell protein expression platform, which is noted for its efficiency in production and reduced costs, to address the unmet healthcare needs in underserved regions.

CEO Mark Emalfarb highlighted the advantages of their C1 technology while Rubic's CEO Dr. Julian Naidoo emphasized the importance of this collaboration for Africa’s healthcare capabilities.

Dyadic International (NASDAQ: DYAI), a biotechnology company, announced its CEO, Mark Emalfarb, will present at the World Vaccine Congress in Washington, D.C. from April 4-6, 2023. Emalfarb's presentation, scheduled for April 5, will focus on transforming manufacturing and bridging technology gaps in vaccine production.

Additionally, he will provide an update on the Phase 1 Clinical Trial for the DYAI-100 COVID-19 vaccine. Key trial milestones include completing dosing in February 2023, with no serious adverse events reported and a full study report expected in the second half of 2023.

Dyadic International (NASDAQ: DYAI) has received regulatory approval for its Phase 1 trial of the DYAI-100 COVID-19 booster vaccine. The trial has successfully completed dosing for both low and high groups with no serious adverse events reported. The company reported a 21.9% year-over-year revenue increase for 2022, reaching approximately $2.93 million. Dyadic maintains cash and investments of $12.7 million, sufficient to fund operations into 2024. Significant collaborations with Janssen, Hengrui, and Phibro have been established, alongside the initiation of the Dapibus™ platform for microbial protein production. A conference call discussing financial results is scheduled for today at 5 PM ET.